These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 4077155)

  • 1. Complement activation in myasthenia gravis plasma by Torpedo acetylcholine receptor liposomes.
    DuPont BL; Koethe SM; McQuillen MP
    Immunol Invest; 1985 Oct; 14(5):415-20. PubMed ID: 4077155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-acetylcholine receptor antibodies in myasthenia gravis: binding to membrane-bound Torpedo AChR.
    Koethe SM; DuPont BL; Calvo AM; Otterson G; McQuillen MP
    Ann N Y Acad Sci; 1987; 505():557-65. PubMed ID: 3479936
    [No Abstract]   [Full Text] [Related]  

  • 3. Expression of human-Torpedo hybrid acetylcholine receptor (AChR) for analysing the subunit specificity of antibodies in sera from patients with myasthenia gravis (MG).
    Loutrari H; Kokla A; Trakas N; Tzartos SJ
    Clin Exp Immunol; 1997 Sep; 109(3):538-46. PubMed ID: 9328134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell responses in EAMG-susceptible and non-susceptible mouse strains after immunization with overlapping peptides encompassing the extracellular part of Torpedo californica acetylcholine receptor alpha chain. Implication to role in myasthenia gravis of autoimmune T-cell responses against receptor degradation products.
    Oshima M; Yokoi T; Deitiker P; Atassi MZ
    Autoimmunity; 1998; 27(2):79-90. PubMed ID: 9583739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How subtle differences in MHC class II affect the severity of experimental myasthenia gravis.
    Yang B; McIntosh KR; Drachman DB
    Clin Immunol Immunopathol; 1998 Jan; 86(1):45-58. PubMed ID: 9434796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence against acetylcholine receptor having a main immunogenic region as target for autoantibodies in myasthenia gravis.
    Lennon VA; Griesmann GE
    Neurology; 1989 Aug; 39(8):1069-76. PubMed ID: 2474772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor.
    Wang ZY; Qiao J; Link H
    J Neuroimmunol; 1993 May; 44(2):209-14. PubMed ID: 8505410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spectrotypic analysis of antibodies to acetylcholine receptors in experimental autoimmune myasthenia gravis.
    Bionda A; De Baets MH; Tzartos SJ; Lindstrom JM; Weigle WO; Theophilopoulos AN
    Clin Exp Immunol; 1984 Jul; 57(1):41-50. PubMed ID: 6611231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo adsorption of autoantibodies in myasthenia gravis using Nanodisc-incorporated acetylcholine receptor.
    Sheng JR; Grimme S; Bhattacharya P; Stowell MH; Artinger M; Prabahakar BS; Meriggioli MN
    Exp Neurol; 2010 Oct; 225(2):320-7. PubMed ID: 20637753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New antigen for antibody detection in myasthenia gravis.
    Gotti C; Mantegazza R; Clementi F
    Neurology; 1984 Mar; 34(3):374-7. PubMed ID: 6538281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Torpedo-mouse hybrid acetylcholine receptors reveals immunodominance of the alpha subunit in myasthenia gravis antisera.
    Loutrari H; Tzartos SJ; Claudio T
    Eur J Immunol; 1992 Nov; 22(11):2949-56. PubMed ID: 1385157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificities of antibody to acetylcholine receptor in rabbits with experimental myasthenia gravis.
    Ueno S; Kang J; Takeuchi H; Takahashi M; Tarui S
    Clin Exp Immunol; 1980 Jul; 41(1):13-8. PubMed ID: 6777100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody to acetylcholine receptor in canine and human myasthenia gravis: differential cross-reactivity with human and rabbit receptor.
    Dau PC; Yano CS; Ettinger SJ
    Neurology; 1979 Jul; 29(7):1065-8. PubMed ID: 572937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of myasthenia gravis antibodies to different acetylcholine receptor preparations.
    Zielinski A; Brenner T; Abramsky O
    Isr J Med Sci; 1982 Apr; 18(4):483-6. PubMed ID: 7085248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
    Atassi MZ; Oshima M; Deitiker P
    Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adsorption column for myasthenia gravis treatment: Medisorba MG-50.
    Nakaji S; Hayashi N
    Ther Apher Dial; 2003 Feb; 7(1):78-84. PubMed ID: 12921120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis.
    Aharonov A; Abramsky O; Tarrab-Hazdai R; Fuchs S
    Lancet; 1975 Aug; 2(7930):340-2. PubMed ID: 51144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor.
    Araga S; LeBoeuf RD; Blalock JE
    Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8747-51. PubMed ID: 8378359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-reactivity of anti-acetylcholine receptor autoantibodies.
    Garlepp MJ; Kay PH; Dawkins RL; Bucknall RC; Kemp A
    Muscle Nerve; 1981; 4(4):282-8. PubMed ID: 7254231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors--Recommendations for methods and experimental designs.
    Losen M; Martinez-Martinez P; Molenaar PC; Lazaridis K; Tzartos S; Brenner T; Duan RS; Luo J; Lindstrom J; Kusner L
    Exp Neurol; 2015 Aug; 270():18-28. PubMed ID: 25796590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.